Measure Lung Health From Hospital to Home

Our technology provides early detection and predictions of worsening diseases for enhanced patient care.

Our flagship product, RESP™ Smart Sensor Platform, is the world’s first FDA-cleared wearable lung device and smart sensor platform for respiratory health–enabling early, remote detection of key changes in lung acoustics and ventilation patterns.

  • Validated Clinical Accuracy
  • Integrates seamlessly with existing EHR clinical workflows
  • Real-time access to lung data via the cloud
  • Cost-effective
  • Small, non-invasive and wireless device

Who We Help

Hospitals + Health Systems

Skilled Nursing Facilities

Clinical Trial Partners

Clinical Trial Partners

Physicians + Group Practices

Payers + Payviders

Real-world, Real-time Monitoring of Lung Health

Our respiratory management solution enables real-world, real-time measuring of lung health by harnessing the power of smart sensor technologies. The RESP™ Smart Sensor Platform collects and calculates the frequency of wheezing, coughing, shortness of breath, as well as respiratory dynamics like rate and excursion for a more holistic picture of each patient’s respiratory heath journey.

The RESP™ biosensor is:

  • Passive and patient-friendly
  • Clinically validated to acquire lung sounds
  • Utilizing proprietary AI algorithms to identify coughing and other adventitious breath sounds such as wheeze, rales, and rhonchi

*Algorithms not part of FDA clearance

RESP™ Smart Sensor Platform is the leading pulmonary management solution revolutionizing lung health

 

It’s now possible to measure lung health anytime, anywhere

Clinically Validated Data
Wireless & Hands Free
Patient-Centered Design
Dynamic Analytics
g
Historical Biomarkers
z
Live Lung Acoustics
The world’s only FDA-cleared biosensor that is clinically validated to detect both coughing, wheezing, ronchi and other adventitious breathing sounds over time without requiring episodic patient intervention.

As demonstrated in 4 ATS publications, RESP can be used continuously and has a much greater sensitivity than intermittent monitoring using an electronic stethoscope. These studies have demonstrated the greater sensitivity of the Strados RESP compared to the Littman electronic stethoscope.

RESP™ offers clinicians a cost-effective, non-invasive and wireless solution that enables early, remote detection of key changes in lung acoustics and ventilation patterns of patients.

It’s a small, unobtrusive, and hands-free biosensor—that many patients forget they are even wearing. The RESP biosensor records and stores every lung sound, whether a patient is sleeping, working out or enjoying time with family.

We designed the RESP biosensor to be non-invasive and comfortable while being easy to use, as it has no wires and is hands-free. This translates into longer wear times and an astounding 99.59% patient compliance. It also means better data for your care team, your physician and a faster time to diagnosis.
Our clinically validated bioacoustic library of sounds and RESP AI engine is the world’s largest entirely hands-free, clinical-grade dataset enabling Strados Labs to be the standard-bearer of acoustic digital biomarkers for clinical research and respiratory care globally.
Current alternatives can only count coughs, while our proprietary technology acquires stethoscope-quality sounds like wheezing, cough spasms, ronchi, and other adventitious lung sound events (including chest wall movements) without requiring episodic patient intervention.
This is a reliable method to objectively detect and effectively communicate the signs and symptoms of these patients with their care teams, in real time and at low cost.

It also provides continuous recording and identification of respiratory signs and symptoms of interest–allowing a better understanding of the progression of the patient’s respiratory status without auscultation by a clinician.

Featured In

Strados Labs Receives FDA 510(k) Clearance for Home Use of its Smart Sensor Platform for Respiratory Health, RESP®

Philadelphia, PA May 3, 2022 — Strados Labs, a medical technology company harnessing the power of smart sensors, machine learning and proprietary algorithms to provide early detection and predictions of worsening respiratory diseases, today announced it has received...

Medtech Company, Strados Labs, Awarded National Science Foundation SBIR Phase II Grant

Funding will help Strados advance the power of its smart sensors to provide early detection and predictions of infectious respiratory diseases Philadelphia, PA, March 10, 2020 — Strados Labs, a medical technology company harnessing the power of smart sensors, machine...

Strados Labs, Growing Medtech Company, Raises $4.5M in Pre-series A Funding Round

Funding to fuel next key milestones as company continues to target asthma, COPD and infectious respiratory diseases in 2022 Philadelphia, PA January 5, 2022 — Strados Labs, a medical technology company harnessing the power of smart sensors, machine learning and...

Procter & Gamble Health Care Veteran, Steve Bishop, Joins Strados Labs Board of Directors

Strados Labs harnesses the power of smart sensors and machine learning to aid in early detection and predictions of worsening respiratory diseases for enhanced patient care   Philadelphia, PA, December 16, 2021 – Strados Labs, a medical technology company harnessing...

Strados Labs Granted CE Mark for its RESP™ Smart Sensor Platform

CE Mark expands the company’s reach to support customers on a global scale Philadelphia, PA, November 18, 2021 – Strados Labs, a medical technology company harnessing the power of smart sensors to aid in early detection and predictions of worsening diseases for...

Strados Labs receives FDA 510(k) clearance for its wireless lung sound measurement platform, RESP™

Philadelphia, PA December 22, 2020 — Strados Labs, a health technology developer of remote respiratory devices and software, today announced it has received FDA Class II 510(k) clearance for its first product, RESP™, a system for measuring, recording and analyzing...

Strados Labs Awarded Competitive Small Business Innovation Grant from the National Science Foundation

Small Business Innovation Research Program Provides Seed Funding for R&D Philadelphia, PA, August 13, 2020 – Strados Labs has been awarded a National Science Foundation (NSF) Phase I Small Business Innovation Research (SBIR) grant for $224,470 to conduct research...

Making Every Breath Count: Innovative Remote E-Stethoscope Platform (RESP) Could Aid Clinicians in Fight Against COVID-19 Outbreak

As hospitals and ICUs begin to fill following the coronavirus outbreak, this remote monitoring platform could save lives, time, and money  Philadelphia, PA, March 19, 2020 – An innovative remote respiratory device created by Strados Labs has the potential to save...

Strados Labs Partners with Harris County Public Health Innovation Lab to Introduce One Breath at a Time Project for Pediatric Asthma Patients

Houston, TX and Philadelphia, PA, August 22, 2019 – An innovative program at Harris County Public Health is aiming to bring remote patient access to under-served Houston children suffering from asthma. Leading-edge technology from Strados Labs, the creator of the...

Strados Labs Adds Health Leaders to Management Team Seasoned Executives Bring Deep Experience to Remote Cardiopulmonary Monitoring Start-Up

Philadelphia, PA, February 12, 2019 — Strados Labs, creator of the world’s first remote respiratory monitoring platform, announced today the addition of three new executives to its management team. Strados Labs’ remote respiratory monitoring platform gives clinicians...

Contact us to try RESP™ today

Talk to our Research team to learn more about how we can help